2,272 reports of this reaction
6.4% of all THEOPHYLLINE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for THEOPHYLLINE, manufactured by Rhodes Pharmaceuticals L.P.. There are 2,272 FDA adverse event reports linking THEOPHYLLINE to DYSPNOEA. This represents approximately 6.4% of all 35,594 adverse event reports for this drug.
Patients taking THEOPHYLLINE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among THEOPHYLLINE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for THEOPHYLLINE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,272 FDA reports for THEOPHYLLINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 6.4% of all adverse event reports for THEOPHYLLINE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking THEOPHYLLINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.